GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.
Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.
www.eosmedchem.com
1.
Crisaborole (AN2728), CAS# 906673-24-3, HPLC 99.2%, HNMR, C13-NMR, LCMS, MSDS, COA, MOA all we provided. pls check:
Name: Crisaborole (AN2728)
CAS#: 906673-24-3
Chemical Formula: C14H10BNO3
Exact Mass: 251.07537
Molecular Weight: 251.0451
Elemental Analysis: C, 66.98; H, 4.01; B, 4.31; N, 5.58; O, 19.12
Appearance: white solid powder
Related CAS #: 906673-24-3 906673-25-4
Synonym: AN2728; AN-2728; AN 2728; Crisaborole
IUPAC/Chemical Name: 4-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)benzonitrile
InChi Key: IQBSCLXAECVABP-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H10BNO3/c16-8-10-1-4-12(5-2-10)19-13-6-3-11-9-18-15(17)14(11)7-13/h1-7,17H,9H2
SMILES Code: N#CC1=CC=C(OC2=CC=C3C(B(O)OC3)=C2)C=C1
2.
Crisaborole (AN2728) Intermediate: 906673-54-9; 906673-45-8; 2973-80-0;
AN2728 Intermediate-1, 4-(4-bromo-3-formylphenoxy)benzonitrile, CAS#906673-54-9, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 1KG in stock.
AN2728 Intermediate-2, 4-(4-broMo-3-(hydroxyMethyl)phenoxy)benzonitrile, CAS#906673-45-8, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 1KG in stock.
AN2728 Intermediate-3, 2-Bromo-5-hydroxybenzaldehyde, CAS#2973-80-0, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 1KG in stock.
TECHNICAL DATA
Appearance: white solid powder
Purity: >98%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
Harmonized System Code: 293490
ADDITIONAL INFORMATION
Related CAS#
CAS#906673-24-3
CAS#906673-25-4
REFERENCES
1: Ciaravino V, Plattner J, Chanda S. An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46. doi: 10.1002/em.21779. Epub 2013 Apr 26. PubMed PMID: 23625818.
2: Freund YR, Akama T, Alley MR, Antunes J, Dong C, Jarnagin K, Kimura R, Nieman JA, Maples KR, Plattner JJ, Rock F, Sharma R, Singh R, Sanders V, Zhou Y. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012 Sep 21;586(19):3410-4. doi: 10.1016/j.febslet.2012.07.058. Epub 2012 Jul 25. PubMed PMID: 22841723.
3: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):47-86. PubMed PMID: 20383346.
4: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633. PubMed PMID: 20094643.
5: Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009 Nov;10(11):1236-42. Review. PubMed PMID: 19876791.
6: Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2129-32. doi: 10.1016/j.bmcl.2009.03.007. Epub 2009 Mar 9. PubMed PMID: 19303290.
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
2018. 4.18 Janpan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
